CORCencora
Price
+12%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, price roughly fair, growth steady, the market undecided.
Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
In the company’s own words · 10-K filed Nov 25, 2025 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Cencora (COR) reported revenue of $84.8B in Q3 2026 (quarter ended Jun 30, 2026), up 5.1% from the same quarter a year earlier. That came with a gross margin of 4.3% and net income of $764M (0.9% of revenue). For the full year FY2025, revenue was $321.3B (+9.3% year on year) and net income $1.55B. Its largest segment in Q3 2026 was US Healthcare Solutions at $74.9B, 92% of the disclosed total, well ahead of International Healthcare Solutions at 8.1%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 25, 2026Director Appointment On September 24, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Robert E. Sanchez to serve on the Board (the “Appointment”), effective October 1, 2026 (the “Effective Date”)Director or officer change · Form 8-K
- Aug 14, 2026On August 13, 2026, following the conclusion of the quarterly meeting of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Lorence H. Kim, M.D., informed the Company of his intent to resign from the Board effective immediately.Director or officer change · Form 8-K
- Aug 5, 2026Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2026 · $81.46BThe company’s own SEC segment disclosure.
- US Healthcare Solutions$74.86B92%
- International Healthcare Solutions$6.60B8%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.